Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01140191 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01140191 is a Phase 2 study that was terminated before completion, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 1 participants.
The verdict
NCT01140191, a Phase 2 study, was terminated before completion, sponsored by U.S. Army Medical Research and Development Command.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The objectives of the study are to evaluate the safety, pharmacokinetics (PK), and efficacy of open label treatment with WR 279,396 (Topical Paromomycin/Gentamicin Cream)in subjects with cutaneous leishmaniasis (CL).
Interventions
- DRUG WR 279,396
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01140191
The ClinicalTrials.gov registry entry for NCT01140191 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WR 279,396 is the first listed.
NCT01140191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01140191 about?
NCT01140191 is a clinical study titled "Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis". The objectives of the study are to evaluate the safety, pharmacokinetics (PK), and efficacy of open label treatment with WR 279,396 (Topical Paromomycin/Gentamicin Cream)in subjects with cutaneous leishmaniasis (CL).
What is the current status of trial NCT01140191?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2013-09. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01140191?
The interventions under investigation include: WR 279,396 (DRUG).
Who is sponsoring clinical trial NCT01140191?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.